PT  - JOURNAL ARTICLE
AU  - EISUKE BOOKA
AU  - HIROTOSHI KIKUCHI
AU  - RYOMA HANEDA
AU  - WATARU SONEDA
AU  - SANSHIRO KAWATA
AU  - TOMOHIRO MURAKAMI
AU  - TOMOHIRO MATSUMOTO
AU  - YOSHIHIRO HIRAMATSU
AU  - HIROYA TAKEUCHI
TI  - Impact of Immune-related Adverse Events on Nivolumab Efficacy in Patients With Upper Gastrointestinal Cancer
AID  - 10.21873/invivo.12506
DP  - 2021 Jul 01
TA  - In Vivo
PG  - 2321--2326
VI  - 35
IP  - 4
4099  - http://iv.iiarjournals.org/content/35/4/2321.short
4100  - http://iv.iiarjournals.org/content/35/4/2321.full
SO  - In Vivo2021 Jul 01; 35
AB  - Background: The development of immune-related adverse events (irAEs) has been found to be associated with survival benefits in some cancers. However, data on the relation between irAEs and gastroesophageal adenocarcinoma (GEA) or esophageal squamous cell carcinoma (ESCC) are scarce. Patients and Methods: We retrospectively reviewed the data of 29 GEA and 21 ESCC patients treated with nivolumab. We investigated the impact of the development of irAEs in GEA and ESCC patients on best overall response and survival. Results: Patients with irAEs had significantly better best overall response, overall survival and progression-free survival than those without irAEs (p=0.007, p<0.001 and p=0.005, respectively). Multivariate analyses identified an Eastern Cooperative Oncology Group performance status ≥2 and the absence of an irAE as independent poor prognostic factors (p<0.001 and 0.016, respectively). Conclusion: The development of irAEs has the potential to predict survival outcomes in patients with GEA and ESCC treated with nivolumab.